Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D3

Experimental Cell Research

Volumn 317, Issue 1, 2011, Pages 117-130

  Zhang, Jing ^a   Harrison, Jonathan S ^b   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

ATF 2; Differentiation; P38MAPK; PU.1; Signaling pathways; Vitamin D

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVATING TRANSCRIPTION FACTOR 2; ANTISENSE OLIGONUCLEOTIDE; CALCITRIOL; CD11B ANTIGEN; CD14 ANTIGEN; CELL SURFACE MARKER; HEAT SHOCK PROTEIN 27; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MIXED LINEAGE KINASE 3; TRANSCRIPTION FACTOR PU 1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 78449302343     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.08.010     Document Type: Article

References (51)

1. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., Yoshiki S., Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc. Natl Acad. Sci. USA 1981, 78:4990-4994.
2. Mangelsdorf D.J., Koeffler H.P., Donaldson C.A., Pike J.W., Haussler M.R. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J. Cell Biol. 1984, 98:391-398.
3. Studzinski G.P., Bhandal A.K., Brelvi Z.S. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. Proc. Soc. Exp. Biol. Med. 1985, 179:288-295.
4. Luong Q.T., Koeffler H.P. Vitamin D compounds in leukemia. J. Steroid Biochem. Mol. Biol. 2005, 97:195-202.
5. Pakkala S., de Vos S., Elstner E., Rude R.K., Uskokovic M., Binderup L., Koeffler H.P. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk. Res. 1995, 19:65-72.
6. Koeffler H.P., Hirji K., Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep. 1985, 69:1399-1407.
7. Wang X., Studzinski G.P. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J. Cell. Biochem. 2001, 80:471-482.
8. Studzinski G.P., Wang X., Ji Y., Wang Q., Zhang Y., Kutner A., Harrison J.S. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J. Steroid Biochem. Mol. Biol. 2005, 97:47-55.
9. Tse A.K., Wan C.K., Shen X.L., Zhu G.Y., Cheung H.Y., Yang M., Fong W.F. 1,25-Dihydroxyvitamin D3 induces biphasic NF-kappaB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/Akt-dependent phosphorylation/degradation of IkappaB. Exp. Cell Res. 2007, 313:1722-1734.
10. Gocek E., Studzinski G.P. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 2009, 46:190-209.
11. Hughes P.J., Marcinkowska E., Gocek E., Studzinski G.P., Brown G. Vitamin D3-driven signals for myeloid cell differentiation-implications for differentiation therapy. Leuk. Res. 2010, 34:553-565.
12. Marcinkowska E. Evidence that activation of MEK1, 2/erk1, 2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res. 2001, 21:499-504.
13. Wang Q., Wang X., Studzinski G.P. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3. J. Cell. Biochem. 2003, 89:1087-1101.
14. Wang X., Studzinski G.P. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J. Cell. Biochem. 2001, 82:68-77.
15. Wang X., Rao J., Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp. Cell Res. 2000, 258:425-437.
16. Manthey C.L., Wang S.W., Kinney S.D., Yao Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J. Leukoc. Biol. 1998, 64:409-417.
17. Karahashi H., Nagata K., Ishii K., Amano F. A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1. Biochim. Biophys. Acta 2000, 1502:207-223.
18. Parmar S., Katsoulidis E., Verma A., Li Y., Sassano A., Lal L., Majchrzak B., Ravandi F., Tallman M.S., Fish E.N., Platanias L.C. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J. Biol. Chem. 2004, 279:25345-25352.
19. Blank V.C., Pena C., Roguin L.P. STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon-alpha2b peptide. Exp. Cell Res. 2010, 316:603-614.
20. Ji Y., Studzinski G.P. Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res. 2004, 64:370-377.
21. Wang Q., Harrison J.S., Uskokovic M., Kutner A., Studzinski G.P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005, 19:1812-1817.
22. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F., Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979, 54:713-733.
23. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line. Int. J. Cancer 1976, 17:565-577.
24. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
25. Zhang J., Harrison J.S., Uskokovic M., Danilenko M., Studzinski G.P. Silibinin can induce differentiation as well as enhance vitamin D(3)-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol. Oncol. 2009, [Epub ahead of print] PMID: 19866452.
26. Zhang J., Posner G.H., Danilenko M., Studzinski G.P. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J. Steroid Biochem. Mol. Biol. 2007, 105:140-149.
27. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
28. Lee J.C., Kassis S., Kumar S., Badger A., Adams J.L. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82:389-397.
29. Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., Han J. Characterization of the structure and function of a new mitogen-activated protein kinase. J. Biol. Chem. 1996, 271:17920-17926.
30. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., O'Neill E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998, 37:13846-13853.
31. Ben-Levy R., Hooper S., Wilson R., Paterson H.F., Marshall C.J. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr. Biol. 1998, 8:1049-1057.
32. Clifton A.D., Young P.R., Cohen P. A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress. FEBS Lett. 1996, 392:209-214.
33. Zayzafoon M., Botolin S., McCabe L.R. P38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose. J. Biol. Chem. 2002, 277:37212-37218.
34. Tindberg N., Porsmyr-Palmertz M., Simi A. Contribution of MAP kinase pathways to the activation of ATF-2 in human neuroblastoma cells. Neurochem. Res. 2000, 25:527-531.
35. Wang X., Studzinski G.P. The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3. Cancer Res. 2006, 66:4402-4409.
36. Han J., Lee J.D., Jiang Y., Li Z., Feng L., Ulevitch R.J. Characterization of the structure and function of a novel MAP kinase kinase. J. Biol. Chem. 1996, 271:2886-2891.
37. Wang X.S., Diener K., Manthey C.L., Wang S., Rosenzweig B., Bray J., Delaney J., Cole C.N., Chan-Hui P.Y., Mantlo N., Lichenstein H.S., Zukowski M., Yao Z. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J. Biol. Chem. 1997, 272:23668-23674.
38. Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., Di Padova F., Ulevitch R.J., Han J. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J. Biol. Chem. 1997, 272:30122-30128.
39. Ono K., Han J. The p38 signal transduction pathway: activation and function. Cell. Signal. 2000, 12:1-13.
40. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 1996, 8:205-215.
41. Thompson T., Danilenko M., Vassilev L., Studzinski G.P. Tumor suppressor p53 status does not determine the differentiation-associated G(1) cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D(3) and antioxidants. Cancer Biol. Ther. 2010, 10:344-350.
42. Pahl H.L., Scheibe R.J., Zhang D.E., Chen H.M., Galson D.L., Maki R.A., Tenen D.G. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J. Biol. Chem. 1993, 268:5014-5020.
43. Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., Lassam N.J. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J. 1996, 15:7026-7035.
44. Brancho D., Ventura J.J., Jaeschke A., Doran B., Flavell R.A., Davis R.J. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol. Cell. Biol. 2005, 25:3670-3681.
45. Hartkamp J., Troppmair J., Rapp U.R. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res. 1999, 59:2195-2202.
46. Shen Y.H., Godlewski J., Zhu J., Sathyanarayana P., Leaner V., Birrer M.J., Rana A., Tzivion G. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J. Biol. Chem. 2003, 278:26715-26721.
47. Zi X., Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem. Biophys. Res. Commun. 1999, 263:528-536.
48. Das D., Pintucci G., Stern A. MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000, 472:50-52.
49. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1alpha, 25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
50. Chen F., Kim E., Wang C.C., Harrison L.E. Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cell. Signal. 2005, 17:1572-1577.
51. Cheung C.W., Gibbons N., Johnson D.W., Nicol D.L. Silibinin-a promising new treatment for cancer. Anticancer Agents Med. Chem. 2010, 10:186-195.